Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Aromatherapy inhaler to reduce distress after a hematopoietic stem cell transplant

Official title: Aromatherapy Inhaler Use for Hematopoietic Stem Cell Transplant Patient Distress

Run by Stanford University · NCT05302583 · Data updated 2026-11-12

We will test whether using a lavender or peppermint aromatherapy inhaler in the first days after a hematopoietic stem cell transplant helps reduce cancer-related distress and improve coping.

More Acute Respiratory Distress Syndrome trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment50 (estimated)
SponsorStanford University
Academic / other
Drugs / interventionsCART, Chimeric Antigen Receptor, chemotherapy
Locations1 site (Stanford, California)
StatusRecruiting
StartedJune 16, 2025
Main results expectedDecember 2026
Study endsDecember 2026
Registry record updatedAugust 12, 2026
Trial IDNCT05302583 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 18 with hematologic malignancies undergoing planned autologous or allogeneic HSCT at Stanford who can consent and are not allergic to lavender or peppermint are the intended participants.

Probably not a fit

Patients allergic to lavender or peppermint, those receiving CAR T-cell therapy, those transplanted for germ cell tumors, or patients with atrial fibrillation, scleroderma, or G6PD deficiency are excluded and unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study provides HSCT patients with a lavender or peppermint aromatherapy inhaler on a single post-transplant day and compares distress and coping to a standard-of-care washout day. The protocol includes an initial aromatherapy day (post-transplant day +1 to +3), a washout day with only standard pharmacologic care, and a follow-up phase day (post-transplant day +3 to +5), with activities occurring on one day per phase. A three-day window for the aromatherapy phases accommodates patients' variable recovery in the immediate post-transplant period. Outcomes focus on short-term changes in distress and coping during the early post-transplant course.

Why it matters

Potential benefit: If effective, aromatherapy inhalers could provide a low-risk, nonpharmacologic option to reduce short-term distress and support coping after HSCT.

How similar studies have gone: Prior small trials of inhaled aromatherapy in cancer and perioperative contexts have shown modest reductions in anxiety and distress, but overall evidence is limited and mixed.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Autologous and Allogeneic patients admitted to E1 for planned HSCT
* Patients with hematologic malignancies requiring HSCT
* No allergies to lavender or peppermint essential oils
* Must have received chemotherapy during preparative regimen (single or multi-agent regimen)
* Adult patient over 18 years of age
* Able to speak, read, and comprehend English
* Willing and capable of providing informed consent

Exclusion Criteria:

* Patients admitted for Chimeric Antigen Receptor T cell (CART) infusion
* Patients receiving a transplant for a germ cell tumor diagnosis
* Unexpected/unplanned admission (e.g., neutropenic fever, confusion, clinical deterioration)
* Immune effector cell-associated neurotoxicity syndrome (ICANS) grade 1 through 4
* History of scleroderma
* History of atrial fibrillation
* Known history of G6PD deficiency
* Allergic to lavender or peppermint essential oils
* Pediatric patient 18 years of age or less
* Unable to speak, read, and comprehend English
* Unwilling or incapable of providing informed consent

Where it's running

  • Stanford University
    Stanford, California, United States
    Recruiting

Study contacts

  • Principal investigator: Anna Oh, PhD, MPH, RN — Stanford University
  • Study coordinator: Anna Oh, PhD, MPH, RN
  • Email: aoh2@stanford.edu
  • Phone: 650-512-6691

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.